{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Disease+Interstitial+Diffuse", "query": { "condition": "Lung Disease Interstitial Diffuse" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 29, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Disease+Interstitial+Diffuse&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T18:57:40.905Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03840928", "title": "PatientSpot Formerly Known as ArthritisPower", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis", "Ankylosing Spondylitis", "Fibromyalgia", "Gout", "Crohn Disease", "Juvenile Idiopathic Arthritis", "Lupus Erythematosus", "Myositis", "Osteoarthritis", "Osteoporosis", "Psoriasis", "Psoriatic Arthritis", "Scleroderma", "Dermatomyositis", "Inflammatory Bowel Diseases", "Polymyositis", "Axial Spondyloarthritis", "Diffuse Idiopathic Skeletal Hyperostosis", "Polymyalgia Rheumatica", "Giant Cell Arteritis", "Temporal Arteritis", "Wegener", "Relapsing Polychondritis", "Undifferentiated Connective Tissue Disease", "Spinal Cord Injuries", "Alzheimer Disease", "Amyotrophic Lateral Sclerosis", "Ataxia", "Bell Palsy", "Brain Tumor", "Cerebral Aneurysm", "Epilepsy", "Guillain-Barre Syndrome", "Headache", "Head Injury", "Hydrocephalus", "Lumbar Disc Disease", "Meningitis", "Multiple Sclerosis", "Muscular Dystrophy", "Neurocutaneous Syndromes", "Parkinson Disease", "Stroke", "Cluster Headache", "Tension-Type Headache", "Chronic Obstructive Pulmonary Disease", "Asthma", "Lung Cancer", "Cystic Fibrosis", "Sleep Apnea", "Eczema", "Alopecia", "Chronic Inflammation", "Unstable Angina", "Heart Attack", "Heart Failure", "Arrythmia", "Valve Heart Disease", "High Blood Pressure", "Congenital Heart Disease", "Peripheral Arterial Disease", "Diabetes", "Chronic Liver Disease", "Obesity" ], "interventions": [], "intervention_types": [], "sponsor": "Global Healthy Living Foundation", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 40000, "start_date": "2015-04-01", "completion_date": "2025-03-01", "has_results": false, "last_update_posted_date": "2023-12-13", "last_synced_at": "2026-07-23T18:57:40.905Z", "location_count": 1, "location_summary": "Upper Nyack, New York", "locations": [ { "city": "Upper Nyack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03840928" }, { "nct_id": "NCT04948554", "title": "A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Sclerosis With and Without Interstitial Lung Disease" ], "interventions": [ { "name": "MK-2225", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2023-03-10", "completion_date": "2023-10-18", "has_results": false, "last_update_posted_date": "2023-11-24", "last_synced_at": "2026-07-23T18:57:40.905Z", "location_count": 11, "location_summary": "La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04948554" }, { "nct_id": "NCT02426229", "title": "Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Scleroderma", "Interstitial Lung Disease" ], "interventions": [ { "name": "dabigatran etexilate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2016-02", "completion_date": "2018-06-21", "has_results": false, "last_update_posted_date": "2018-07-13", "last_synced_at": "2026-07-23T18:57:40.905Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02426229" }, { "nct_id": "NCT05878717", "title": "A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Systemic Sclerosis Associated Interstitial Lung Disease", "Scleroderma, Systemic" ], "interventions": [ { "name": "Belimumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2023-09-13", "completion_date": "2029-07-12", "has_results": false, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-07-23T18:57:40.905Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05878717" }, { "nct_id": "NCT06843239", "title": "Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Sclerosis (SSc)", "Scleroderma" ], "interventions": [ { "name": "Tibulizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Zura Bio Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 80, "start_date": "2025-02-06", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-07-23T18:57:40.905Z", "location_count": 7, "location_summary": "La Jolla, California • Los Angeles, California • Plantation, Florida + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Plantation", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06843239" }, { "nct_id": "NCT03975829", "title": "Pediatric Long-Term Follow-up and Rollover Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diffuse Astrocytoma", "Anaplastic Astrocytoma", "Astrocytoma", "Oligodendroglioma, Childhood", "Anaplastic Oligodendroglioma", "Glioblastoma", "Pilocytic Astrocytoma", "Giant Cell Astrocytoma", "Pleomorphic Xanthoastrocytoma", "Anaplastic Pleomorphic Xanthoastrocytoma", "Angiocentric Glioma", "Chordoid Glioma of Third Ventricle", "Gangliocytoma", "Ganglioglioma", "Anaplastic Ganglioglioma", "Dysplastic Gangliocytoma of Cerebrellum", "Desmoplastic Infantile Astrocytoma and Ganglioglioma", "Papillary Glioneuronal Tumor", "Rosette-forming Glioneuronal Tumor", "Central Neurocytoma", "Extraventricular Neurocytoma", "Cerebellar Liponeurocytoma", "Neurofibromatosis Type 1" ], "interventions": [ { "name": "dabrafenib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "99 Years", "sex": "ALL", "summary": "1 Year to 99 Years" }, "enrollment_count": 163, "start_date": "2019-11-04", "completion_date": "2026-11-05", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-07-23T18:57:40.905Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia • Miami, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03975829" }, { "nct_id": "NCT01257802", "title": "GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lupus Erythematosus, Systemic", "Systemic Vasculitis", "Isolated Angiitis of Central Nervous System", "Lung Disease With Systemic Sclerosis", "Lung Disease Interstitial Diffuse" ], "interventions": [ { "name": "depot leuprolide acetate 3.75 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joseph Mccune", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 14, "start_date": "2011-05", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-06-27", "last_synced_at": "2026-07-23T18:57:40.905Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan • Columbus, Ohio", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01257802" }, { "nct_id": "NCT00764309", "title": "Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Scleroderma" ], "interventions": [ { "name": "dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2009-01", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2012-02-29", "last_synced_at": "2026-07-23T18:57:40.905Z", "location_count": 13, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Farmington, Connecticut + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00764309" }, { "nct_id": "NCT05270668", "title": "Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Cutaneous Systemic Sclerosis", "Interstitial Lung Disease" ], "interventions": [ { "name": "Tulisokibart", "type": "DRUG" }, { "name": "Companion diagnostic ( CDx)", "type": "DIAGNOSTIC_TEST" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2022-03-29", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-07-23T18:57:40.905Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05270668" }, { "nct_id": "NCT07047690", "title": "A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Sclerosis" ], "interventions": [ { "name": "Nemolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galderma R&D", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2026-02-20", "completion_date": "2028-07-23", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-07-23T18:57:40.905Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan • Arlington, Texas", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Arlington", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07047690" } ] }